The goal of the Tissue and Cell Molecular Analysis (TACMA) Shared Resource of the Mayo Clinic Cancer Center is to provide histological and related tissue-based services to Cancer Center investigators. The TACMA Shared Resource is a source of expertise and collaborative support for Cancer Center investigators, providing services for preparation of histology slides for microscopy, tissue microarray construction, immunostaining, digital image capture and analysis, laser capture microdissection, and preparation of tissues for subsequent nucleic acid or protein extraction. Since 2003, the number of Cancer Center members who have used services provided by the TACMA Shared Resource increased from 84 to 97 (15%). More importantly, the level of use of the four of the five major TACMA services by Cancer Center members increased 33%, 71%, 100%, and 209% and the other major service had modest growth of 7%. Cancer Center members continue to account for more than 50% of the total demand for each service offered by TACMA. This growth has been achieved by adding technical staff positions, by expanding hours of operation, and by purchasing additional equipment in order to increase our capacity for services in keeping with the demand for services. The services provided by the TACMA Shared Resource have been vital to cancer research at Mayo Clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-38
Application #
8382229
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$165,176
Indirect Cost
$69,531
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications